WNY0824
WNY0824 (PLK1/BRD4-IN-1) is an orally active dual inhibitor of PLK1 and BET protein families, with IC50 values of 22, 402.5, 150.7, 103.9, and 311.9 nmol/L for PLK1, BRD2, BRD3, BRD4, and BRDT, respectively. WNY0824 induces cell cycle arrest and apoptosis by inhibiting AR- and MYC-mediated transcriptional processes. In addition, WNY0824 also inhibits tumor growth in Enzalutamide resistant CRPC xenograft tumor models[1][2].
Product Specifications
CAS Number
2412707-81-2
Product Name Alternative
PLK1/BRD4-IN-1
UNSPSC
12352005
Target
Androgen Receptor; Apoptosis; c-Myc; Epigenetic Reader Domain; Polo-like Kinase (PLK)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Vitamin D Related/Nuclear Receptor
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/wny0824.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1CCN(C)CC1)C2=CC=C(NC(N=C3N(CC4CCCCC4)[C@@H]5CC)=NC=C3N6C5=NN=C6C)C(OC)=C2
Molecular Formula
C31H43N9O2
Molecular Weight
573.73
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD2; BRD3; BRD4; BRDT; PLK1
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD10 (CB-CALLA), CF488A conjugate, 0.1mg/mL
